Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing

Hely Ollila-Raj; Astrid Murumägi; Teijo Pellinen; Mariliina Arjama; Eva Sutinen; Kirsi Volmonen; Heidi M. Haikala; Olli Kallioniemi; Mikko I. Mäyränpää; Ilkka Ilonen

doi:10.1016/j.lungcan.2023.02.024

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing

Hely Ollila-Raj, Astrid Murumägi, Teijo Pellinen, Mariliina Arjama, Eva Sutinen, Kirsi Volmonen, Heidi M. Haikala, Olli Kallioniemi, Mikko I. Mäyränpää, Ilkka Ilonen

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Lung Cancer
Volume	178
Issue number	178
Pages (from-to)	213-219
Number of pages	7
ISSN	0169-5002
DOIs	https://doi.org/10.1016/j.lungcan.2023.02.024 https://doi.org/10.1016/j.lungcan.2023.02.024
Publication status	Published - Apr 2023
MoE publication type	A1 Journal article-refereed

Fields of Science

3122 Cancers
3121 General medicine, internal medicine and other clinical medicine

Access to Document

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testingFinal published version, 463 KB

Keuhkopussin mesoteliooman kasvainmikroympäristö: uudet ennustetekijät ja lääkehoidon kohteet
Mikko Mäyränpää (Supervisor)
2019 → Oct 2023
Activity: Examination types › Supervisor or co-supervisor of doctoral thesis

Cite this

Ollila-Raj, H., Murumägi, A., Pellinen, T., Arjama, M., Sutinen, E., Volmonen, K., Haikala, H. M., Kallioniemi, O., Mäyränpää, M. I., & Ilonen, I. (2023). Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing. Lung Cancer, 178(178), 213-219. https://doi.org/10.1016/j.lungcan.2023.02.024, https://doi.org/10.1016/j.lungcan.2023.02.024

@article{40022c5b0bac4dc4b1e4215e7844b862,

title = "Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing",

keywords = "Drug sensitivity testing, Pleural mesothelioma, Prexasertib, mTOR inhibitors, 3122 Cancers, 3121 General medicine, internal medicine and other clinical medicine",

author = "Hely Ollila-Raj and Astrid Murum{\"a}gi and Teijo Pellinen and Mariliina Arjama and Eva Sutinen and Kirsi Volmonen and Haikala, {Heidi M.} and Olli Kallioniemi and M{\"a}yr{\"a}np{\"a}{\"a}, {Mikko I.} and Ilkka Ilonen",

year = "2023",

month = apr,

doi = "10.1016/j.lungcan.2023.02.024",

language = "English",

volume = "178",

pages = "213--219",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "ELSEVIER IRELAND LTD",

number = "178",

}

Ollila-Raj, H, Murumägi, A , Pellinen, T , Arjama, M , Sutinen, E, Volmonen, K, Haikala, HM, Kallioniemi, O , Mäyränpää, MI & Ilonen, I 2023, 'Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing', Lung Cancer, vol. 178, no. 178, pp. 213-219. https://doi.org/10.1016/j.lungcan.2023.02.024, https://doi.org/10.1016/j.lungcan.2023.02.024

TY - JOUR

T1 - Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing

AU - Ollila-Raj, Hely

AU - Murumägi, Astrid

AU - Pellinen, Teijo

AU - Arjama, Mariliina

AU - Sutinen, Eva

AU - Volmonen, Kirsi

AU - Haikala, Heidi M.

AU - Kallioniemi, Olli

AU - Mäyränpää, Mikko I.

AU - Ilonen, Ilkka

PY - 2023/4

Y1 - 2023/4

KW - Drug sensitivity testing

KW - Pleural mesothelioma

KW - Prexasertib

KW - mTOR inhibitors

KW - 3122 Cancers

KW - 3121 General medicine, internal medicine and other clinical medicine

U2 - 10.1016/j.lungcan.2023.02.024

DO - 10.1016/j.lungcan.2023.02.024

M3 - Article

C2 - 36878102

SN - 0169-5002

VL - 178

SP - 213

EP - 219

JO - Lung Cancer

JF - Lung Cancer

IS - 178

ER -

Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing

Fields of Science

Access to Document

Activities

Keuhkopussin mesoteliooman kasvainmikroympäristö: uudet ennustetekijät ja lääkehoidon kohteet

Cite this